Medical news and careers, clearly connected
CareZelo
English
Menu

Public health updates

Public healthCanada

Roche to discontinue Activase rt-PA clot drug on Jan 31, 2027

Hoffmann-La Roche reports its Activase rt-PA (alteplase) 100 mg powder for solution is to be discontinued on Jan 31, 2027, for business reasons. Roche says the decision is voluntary and not due to quality, safety or efficacy issues, and remaining supply is listed to Nov 30, 2027.

Alteplase is the clot-busting drug used for stroke and heart attack care — hospitals should plan the switch to alternative treatments.

Discontinuation expected: Jan 31, 2027 All deadlines

Ask about this brief

Answers are written by AI from this brief and can be wrong. Check the original source before you act.

2 free questions a day without an account. Members ask as often as they like, free.

Not medical, legal or immigration advice.

Read the original

Official source: Roche to discontinue Activase rt-PA clot drug on Jan 31, 2027 (opens in a new tab) — Health Product Shortages Canada

Report a problem

Due in 43 daysPublic healthCanada

Manufacturing disruption causes shortage of Combigan glaucoma eye drops until December 11

AbbVie reports its Combigan (timolol / brimonidine tartrate) 0.5% / 0.2% ophthalmic solution is in an actual shortage after a disruption in manufacturing. The actual shortage began Sep 9, 2026 and is estimated to end Dec 11, 2026.

Combigan is a widely used glaucoma eye drop — patients and pharmacies should check stock and alternatives while the shortage runs.

Official source: Health Product Shortages Canada (opens in a new tab)

Due in 29 daysPublic healthCanada

Glenmark reports 40 mg olmesartan tablet shortage through November 27

Glenmark Pharmaceuticals Canada reports its GLN-Olmesartan (olmesartan medoxomil) 40 mg tablet is in an actual shortage that began Oct 29, 2026, driven by an increase in demand. The shortage is estimated to end Nov 27, 2026.

Olmesartan is a widely prescribed blood pressure drug — pharmacies should check stock and alternatives while the shortage runs.

Official source: Health Product Shortages Canada (opens in a new tab)

Due in 29 daysPublic healthCanada

Glenmark reports supply shortage of 20 mg olmesartan HCTZ tablets until November

Glenmark Pharmaceuticals Canada reports its GLN-Olmesartan HCTZ (olmesartan medoxomil / hydrochlorothiazide) 20 mg / 12.5 mg tablet is in an actual shortage that began Oct 29, 2026, driven by an increase in demand. The shortage is estimated to end Nov 27, 2026.

Olmesartan/HCTZ is a widely prescribed blood pressure combination — pharmacies should check stock and alternatives while the shortage runs.

Official source: Health Product Shortages Canada (opens in a new tab)

Public healthCanada

Pfizer reports ongoing manufacturing shortage of Premarin vaginal cream

Pfizer Canada reports its Premarin (conjugated estrogens) 0.625 mg vaginal cream is in an actual shortage after a disruption in manufacturing. The actual shortage began Jun 30, 2026 and no estimated end date is given.

Premarin cream is widely used for menopause-related vaginal symptoms — patients and pharmacies should check stock and alternatives while the shortage runs.

Official source: Health Product Shortages Canada (opens in a new tab)